Literature DB >> 9703001

MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children.

C A Felix1, M R Hosler, D J Slater, R I Parker, M Masterson, J A Whitlock, T R Rebbeck, P C Nowell, B J Lange.   

Abstract

PURPOSE: To assess translocation breakpoint distribution within the MLL genomic breakpoint cluster region (bcr), 40 cases of de novo leukemia in children were examined by karyotype and Southern blot analysis. PATIENTS AND METHODS: Criteria for inclusion were karyotypic or molecular rearrangement of chromosome band 11q23. Of the 40 cases, 31 occurred in infants. Twenty cases were acute lymphoblastic leukemia (ALL), 17 were acute myeloid leukemia (AML), and 3 were biphenotypic.
RESULTS: Karyotype identified 27 cases with translocation of chromosome band 11q23 and 2 with abnormalities of band 11q13 but not 11q23. Southern blot analysis showed rearrangement within the MLL genomic bcr in 38 of the 40 cases. In these 38, additional probe-restriction digest combinations localized MLL genomic breakpoints to the 5' portion of the bcr in 14 cases and to the 3' portion in 18; material was insufficient for further localization to 5' or 3' within the bcr in 6 cases. In the two remaining cases, both with t(4;11)(q21;q23), one breakpoint mapped 5' of the bcr between intron 3 and exon 5, whereas the other breakpoint was neither within nor 5' of the MLL genomic bcr.
CONCLUSIONS: Suggested trends warranting investigation in more patients were breakpoint sites in the 3' bcr in AML and in patients older than 12 months. The distribution of MLL genomic breakpoints within the bcr in de novo leukemia in children is distinct from that in adults, where the breakpoints cluster in the 5' portion of the bcr.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703001     DOI: 10.1097/00043426-199807000-00004

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  8 in total

1.  An optimized technology platform for the rapid multiplex molecular analysis of genetic alterations associated with leukemia.

Authors:  Fei Ye; Walairat Laosinchai-Wolf; Emmanuel Labourier
Journal:  Cancer Genet       Date:  2012-09-29

Review 2.  DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.

Authors:  Maria Teresa Esposito; Chi Wai Eric So
Journal:  Chromosoma       Date:  2014-08-12       Impact factor: 4.316

3.  Panhandle PCR for cDNA: a rapid method for isolation of MLL fusion transcripts involving unknown partner genes.

Authors:  M D Megonigal; E F Rappaport; R B Wilson; D H Jones; J A Whitlock; J A Ortega; D J Slater; P C Nowell; C A Felix
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 4.  Perspectives on the causes of childhood leukemia.

Authors:  Joseph Wiemels
Journal:  Chem Biol Interact       Date:  2012-02-02       Impact factor: 5.192

5.  Association of CYP3A4 genotype with treatment-related leukemia.

Authors:  C A Felix; A H Walker; B J Lange; T M Williams; N J Winick; N K Cheung; B D Lovett; P C Nowell; I A Blair; T R Rebbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

6.  The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features.

Authors:  Denise Ragusa; Evgeny M Makarov; Oliver Britten; Daniela Moralli; Catherine M Green; Sabrina Tosi
Journal:  Cancer Rep (Hoboken)       Date:  2019-08-07

7.  Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.

Authors:  Ashutosh Kumar; Marilyn Ehrenshaft; Erik J Tokar; Ronald P Mason; Birandra K Sinha
Journal:  Biochim Biophys Acta       Date:  2016-04-17

Review 8.  Systematic Classification of Mixed-Lineage Leukemia Fusion Partners Predicts Additional Cancer Pathways.

Authors:  Rolf Marschalek
Journal:  Ann Lab Med       Date:  2016-03       Impact factor: 3.464

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.